Antibody and utilization of the same
View Patent ↗The present invention is directed to providing an antibody having greater reactivity with amylospheroid than with amyloid β fibers, and the like. The aforementioned antibody includes an antibody having activity of inhibiting amylospheroid formation or activity of inhibiting neuronal cell death induced by amylospheroid. The antibody can be used for a therapeutic and/or preventive agent for Alzheimer's disease, or a screening thereof, a method and reagent for detecting individuals with Alzheimer's disease, and the like.
1. An isolated monoclonal antibody, wherein the antibody exhibits greater reactivity with amylospheroid than with amyloid β fibers and monomeric amyloid β, and has
(i) activity of inhibiting neuronal cell death induced by amylospheroid or
(ii) activity of inhibiting amylospheroid formation, and
wherein the reactivity of the antibody with amylospheroid is competitively inhibited more potently by the five-residues-peptide of positions 2 to 6 of the sequence of SEQ ID NO: 2 than any other remaining 37 kinds of five-residues-peptides which can be generated from the sequence of SEQ ID NO: 2.
2. The antibody according to claim 1 , which exhibits reactivity with amylospheroid to a degree that is at least twice as great as that of its reactivity with amyloid β fibers in an experimental system wherein the reactivity of an antibody with amylospheroid is compared with its reactivity with amyloid β fibers at the same antibody concentration, antibody amount, antigen protein concentration, and antigen protein amount.
3. The antibody according to claim 1 , which exhibits reactivity with amylospheroid to a degree that is at least ten times as great as that of its reactivity with amyloid β fibers in an experimental system wherein reactivity of an antibody with amylospheroid is compared with its reactivity with amyloid β fibers at the same antibody concentration, antibody amount, antigen protein concentration, and antigen protein amount.
4. The antibody according to claim 1 , which exhibits reactivity with amylospheroid to a degree that is at least twice as great as that of its reactivity with monomeric amyloid β protein in an experimental system wherein reactivity of an antibody with amylospheroid is compared with its reactivity with monomeric amyloid β protein at the same antibody concentration, antibody amount, antigen protein concentration, and antigen protein amount.
5. The antibody according to claim 1 , which exhibits reactivity with amylospheroid to a degree that is at least five times as great as that of its reactivity with monomeric amyloid β protein in an experimental system wherein reactivity of an antibody with amylospheroid is compared with its reactivity with monomeric amyloid β protein at the same antibody concentration, antibody amount, antigen protein concentration, and antigen protein amount.
6. The antibody according to claim 1 , which is obtained using amylospheroid as an antigen.
7. The monoclonal antibody according to claim 1 , which has the dissociation constant with amylospheroid of not more than 10 −9 .
8. The antibody according to claim 1 , which recognizes an epitope near the N terminus of monomeric amyloid β protein.
9. A neuron protector which comprises the antibody according to claim 1 .
10. An inhibitor of amylospheroid formation which comprises the antibody according to claim 1 .
11. A reagent for detecting Alzheimer's disease which comprises the antibody according to claim 1 .
12. A medicine which comprises the antibody according to claim 1 .
13. A therapeutic agent for Alzheimer's disease which comprises the antibody according to claim 1 .
14. A method for screening for a therapeutic agent for Alzheimer's disease, which comprises bringing an analyte and the antibody according to claim 1 into contact with amylospheroid and selecting a candidate by using the affinity of the analyte with amylospheroid as an indicator.
15. A method for detecting individuals with Alzheimer's disease which comprises bringing a biological sample obtained from an individual suspected of Alzheimer's disease into contact with the antibody according to claim 1 and assaying the presence or absence of a substance that reacts with the antibody in the sample.
16. A method for treating Alzheimer's disease, which comprises administering to a patient in need a therapeutically effective amount of a monoclonal antibody, wherein the antibody exhibits greater reactivity with amylospheroid than with amyloid β fibers and monomeric amyloid β, and has
(i) activity of inhibiting neuronal cell death induced by amylospheroid or
(ii) activity of inhibiting amylospheroid formation, and
wherein the reactivity of the antibody with amylospheroid is competitively inhibited more potently by the five-residues-peptide of positions 2 to 6 of the sequence of SEQ ID NO: 2 than any other remaining 37 kinds of five-residues-peptides which can be generated from the sequence of SEQ ID NO: 2.
17. The method according to claim 16 , wherein the antibody exhibits reactivity with amylospheroid to a degree that is at least twice as great as that of its reactivity with amyloid β fibers in an experimental system wherein the reactivity of an antibody with amylospheroid is compared with its reactivity with amyloid β fibers at the same antibody concentration, antibody amount, antigen protein concentration, and antigen protein amount.
18. The method according to claim 16 , wherein the antibody exhibits reactivity with amylospheroid to a degree that is at least ten times as great as that of its reactivity with amyloid β fiber in an experimental system wherein reactivity of an antibody with amylospheroid is compared with its reactivity with amyloid β fibers at the same antibody concentration, antibody amount, antigen protein concentration, and antigen protein amount.
19. The method according to claim 16 , wherein the antibody exhibits reactivity with amylospheroid to a degree that is at least twice as great as that of its reactivity with monomeric amyloid β protein in an experimental system wherein reactivity of an antibody with amylospheroid is compared with its reactivity with monomeric amyloid β protein at the same antibody concentration, antibody amount, antigen protein concentration, and antigen protein amount.
20. The method according to claim 16 , wherein the antibody exhibits reactivity with amylospheroid to a degree that is at least five times as great as that of its reactivity with monomeric amyloid β protein in an experimental system wherein reactivity of an antibody with amylospheroid is compared with its reactivity with monomeric amyloid β protein at the same antibody concentration, antibody amount, antigen protein concentration, and antigen protein amount.
21. The method according to claim 16 , wherein the antibody is obtained using amylospheroid as an antigen.
22. The method according to claim 16 , wherein the antibody has a dissociation constant with amylospheroid of not more than 10 −9 .
23. The method according to claim 16 , wherein the antibody recognizes the N′ terminus of the monomeric amyloid β protein as an epitope.
24. A monoclonal antibody which is produced by a hybridoma having any of the accession number (receipt number): FERM ABP-10392, FERM ABP-10393, or FERM ABP-10394.
25. A hybridoma having any of the accession number (receipt number): FERM ABP-10392, FERM ABP-10393, or FERM ABP-10394.
26. A neuron protector which comprises the antibody according to claim 24 .
27. An inhibitor of amylospheroid formation which comprises the antibody according to claim 24 .
28. A reagent for detecting Alzheimer's disease which comprises the antibody according to claim 24 .
29. A medicine which comprises the antibody according to claim 24 .
30. A therapeutic agent for Alzheimer's disease which comprises the antibody according to claim 24 .
31. A method for screening for a therapeutic agent for Alzheimer's disease, which comprises bringing an analyte and the antibody according to claim 24 into contact with amylospheroid and selecting a candidate by using the affinity of the analyte with amylospheroid as an indicator.
32. A method for detecting individuals with Alzheimer's disease which comprises bringing a biological sample obtained from an individual suspected of Alzheimer's disease into contact with the antibody according to claim 24 and assaying the presence or absence of a substance that reacts with the antibody in the sample.
33. A method for treating Alzheimer's disease, which comprises administering to a patient in need a therapeutically effective amount of a monoclonal antibody, wherein the antibody is a monoclonal antibody produced by a hybridoma having accession number FERM ABP-10392, FERM ABP-10393, or FERM ABP-10394.